Cross-Border Corridor
24%
US to China, Korea, and Japan — accelerating deal velocity.
The China-to-West licensing wave reset comp benchmarks across 2023–2026. Korean platform deal acceleration has emerged as a distinct sub-corridor. Japanese mid-pharma in-licensing strategy creates opportunities for US-originated assets seeking Asian market access.
Corridor Data
Deal Coverage
24% of deal flow
Key Benchmark
Korean biotech deal volume increased 3x from 2023 to 2025
Discuss your cross-border transaction.
We’ll meet you at peer level — anywhere in the world.